Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study
- PMID: 37894355
- PMCID: PMC10605800
- DOI: 10.3390/cancers15204990
Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study
Abstract
Distinguishing treatment-related abnormalities (TRA) from tumor progression (TP) in glioblastoma patients is a diagnostic imaging challenge due to the identical morphology of conventional MR imaging sequences. Diffusion-weighted imaging (DWI) and its derived images of the apparent diffusion coefficient (ADC) have been suggested as diagnostic tools for this problem. The aim of this study is to determine the diagnostic accuracy of different cut-off values of the ADC to differentiate between TP and TRA. In total, 76 post-treatment glioblastoma patients with new contrast-enhancing lesions were selected. Lesions were segmented using a T1-weighted, contrast-enhanced scan. The mean ADC values of the segmentations were compared between TRA and TP groups. Diagnostic accuracy was compared by use of the area under the curve (AUC) and the derived sensitivity and specificity values from cutoff points. Although ADC values in TP (mean = 1.32 × 10-3 mm2/s; SD = 0.31 × 10-3 mm2/s) were significantly different compared to TRA (mean = 1.53 × 10-3 mm2/s; SD = 0.28 × 10-3 mm2/s) (p = 0.003), considerable overlap in their distributions exists. The AUC of ADC values to distinguish TP from TRA was 0.71, with a sensitivity and specificity of 65% and 70%, respectively, at an ADC value of 1.47 × 10-3 mm2/s. These findings therefore indicate that ADC maps should not be used in discerning between TP and TRA at a certain timepoint without information on temporal evolution.
Keywords: apparent diffusion coefficient; diffusion imaging; glioblastoma; receiver operating characteristic curve; treatment-related abnormality; tumor progression.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Merkel A., Soeldner D., Wendl C., Urkan D., Kuramatsu J.B., Seliger C., Proescholdt M., Eyupoglu I.Y., Hau P., Uhl M. Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials. J. Neuro Oncol. 2017;132:249–254. doi: 10.1007/s11060-016-2362-z. - DOI - PMC - PubMed
-
- Hagiwara A., Schlossman J., Shabani S., Raymond C., Tatekawa H., Abrey L.E., Garcia J., Chinot O., Saran F., Nishikawa R., et al. Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation. J. Neuro Oncol. 2022;159:509–518. doi: 10.1007/s11060-022-04088-3. - DOI - PubMed
LinkOut - more resources
Full Text Sources
